HomeQuestion
How do you manage a HR-/HER2+ breast cancer patient with local progression during neoadjuvant TCHP?
2
1 Answers
Mednet Member
Medical Oncology · Winship Cancer Institute and Emory University School of Medicine
With the robust activity of HER2-targeted agents in the operable setting, this is a highly concerning clinical scenario. I would retest for HER2 on the biopsy specimen and confirm its positivity. Also, I have significantly limited the use of anthracyclines in patients with HER2+ breast cancer - give...